1WAGNER J G,NELSON E.Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug[J].J Pharm Sci,1964,53:1392-1403. 被引量：1
2WANG Y,NEDELMAN J.Bias in the Wagner-Nelson estimate of the fraction of drug absorbed[J].Pharm Res,2002,19(4):470476. 被引量：1
4USP-NF:In vitro-in vivo correlations[S].The United States pharmacopoeial convention Inc.Rockville,2002:2163-2165. 被引量：1
5U.S.Department of Health and Human Services Food and Drug Administration,Center for Drug Evaluation and Research (CDER).Guidance for industry,extended release oral dosage forms:development,evaluation,and application of in vitro/in vivo correlations[EB/OL].1997:www.fda.gov/CDER/guidance/1306fnl.pdf 被引量：1
7ABSHAGEN U.Pharmacokinetics of ISDN,sustained-release ISDN,and IS-5-MN.In:COHN JN,RITTTNGBAUSEN R (eds)[M].Mononitrates.Berlin:Springer Verleg,1985:53. 被引量：1
8LAUFEN H,AUMANN M,LEITOLD M.Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man[J].Arzneimittelforschung,1983,33(7):980-984. 被引量：1
9MAJOR R M,TALOR T,CHASSEAUD L F,et al.Isosorbide-5-mononitrate kinetics[J].Clin Pharmacol Ther,1984,35 (5):653-659. 被引量：1
10STEUDELP,GALEAZZIRL,SOLIVAM.Isosorbide5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing[J].Clin Pharmacol Ther,1984,36(4):485-492. 被引量：1
